FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Disclosed is a composition for preventing, treating or diagnosing an eye disease associated with amyloid-beta related pathological abnormalities or changes in visual system tissues. Composition contains an effective amount of amyloid beta-binding antibody. Also disclosed is a method of protecting visual retinal ganglion cells from amyloid-beta induced neuronal degradation, as well as methods of diagnosing, preventing, treating, facilitating development, monitoring minimal residual manifestations, predicting sensitivity of a subject to treatment of eye diseases associated with amyloid-beta related pathological abnormalities or changes. Said methods involve administering a composition containing an antibody to amyloid-beta to a subject.
EFFECT: invention can be used in treating ophthalmic diseases.
68 cl, 20 dwg, 14 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2542967C2 |
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| MONOCLONAL BODY AGAINST AMYLOID BETA | 2008 |
|
RU2571856C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
| METHOD OF USE IN THERAPY | 2010 |
|
RU2579659C2 |
| SAFE AND FUNCTIONAL HUMANIZED ANTIBODIES | 2011 |
|
RU2607368C2 |
| THERAPEUTIC VACCINE | 2006 |
|
RU2440824C2 |
